While there are some early signs of promise with the company’s vaccine, Inovio has released only bare-bones data from the first phase of clinical trials. Shareholders have sued Inovio, claiming it has exaggerated its progress on a coronavirus vaccine to inflate its stock price. Inovio’s stock price plunged 66%, although it would soon soar to new heights, thanks to optimism about its potential vaccine. While the company does manufacture its Cellectra, it has relied on another company, VGX International, to manufacture its vaccine candidate. “Although the COVID-19 pandemic is horrible, Inovio is unlikely to win the race for the vaccine,” VGX lawyers wrote.

Source: bd News24 August 09, 2020 19:41 UTC